Category: 23256-42-0

On May 18, 2018, Zhang, Jiaojiao published a patent.Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Veterinary composition for preventing and treating infectious pleuropneumonia and mycoplasma pneumonia in fowls. And the patent contained the following:

The title veterinary composition comprises (by weight parts) tylosin tartrate 8-10, aminopyrine 10-20, trimethoprim lactate 10-20, thenardite 8-12 and oral glucose 8-12. The inventive veterinary composition has good efficacy, no harm, no residue and convenient use, and can be used for preventing and treating infectious pleuropneumonia and mycoplasma pneumonia in fowls. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to veterinary drug fowl infectious pleuropneumonia mycoplasma pneumonia, Pharmaceuticals: Formulation and Compounding and other aspects.Safety of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On May 8, 2013, Liu, Yuanyuan; Hao, Zhihui; Wang, Yanling published a patent.Recommanded Product: 23256-42-0 The title of the patent was Soluble powder for treating toxoplasmosis and its preparation method. And the patent contained the following:

This invention provides a soluble powder for treating toxoplasmosis and its preparation method. The title soluble powder comprises sulfamethazine, lactic acid TMP, lincomycin hydrochloride and anhydrous glucose, can be used for treating toxoplasmosis in animals. The formulation can be used after mixing or mixed with water. The soluble powder has low cost and good effect, and is suitable for industrialized production The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Recommanded Product: 23256-42-0

The Article related to soluble powder toxoplasmosis sulfamethazine lincomycin trimethoprim, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On October 15, 2014, Wang, Yuwan; Pan, Zhende; Peng, Xin; Guo, Qiang; Dai, Xiaoxi; Ren, Yanan; Shen, Li published a patent.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was A preparation method of tulathromycin emulsifiable injection. And the patent contained the following:

A tulathromycin emulsifiable injection (per litre) comprises tulathromycin 60-200 g, poloxamer 188 30-120 g, an antioxidant 0.3-0.6 g, and an oil medium in balance. A proper amount of hydrogenated castor oil and soybean lecithin can also be added in the injection. It is characterized in that emulsification occurs to the injection when meeting water (or fluid) to form a mixed system of emulsion droplets and oil. The injection has both quick-release and long acting effects, also has a high drug-loading amount, good stability, and good biocompatibility. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to tulathromycin emulsification injection veterinary drug poloxamer, Pharmaceuticals: Formulation and Compounding and other aspects.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 13, 2021, Xie, Yanjun; Cao, Haifeng; Zhu, Yuandong; Zhu, Xuefeng; Cao, Yonghui; Liu, Guodong published a patent.Synthetic Route of 23256-42-0 The title of the patent was Preparation method of soluble florfenicol powder. And the patent contained the following:

The invention discloses a preparation method of soluble florfenicol powder. The soluble florfenicol powder is prepared from the following raw materials in parts by mas: 5-15 parts of florfenicol, 2-5 parts of beta-cyclodextrin, 3-7 parts of polyethylene glycol, 2-6 parts of silicon dioxide, 2-5 parts of acidic auxiliary materials and 2-3 parts of bactericidal ingredients. The florfenicol slow-release taste-masking preparation prepared by the process successfully solves the problem of poor palatability of florfenicol, masks the bitter taste of the medicine, increases the palatability, and greatly improves the appetite of animals; and according to the florfenicol slow-release taste-masking preparation, the drug florfenicol is successfully wrapped in the beta-cyclodextrin, so that the drug can be slowly released, the sustained-release effect is achieved, the drug action time is prolonged, the curative effect of the drug is improved, and the bioavailability is improved. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Synthetic Route of 23256-42-0

The Article related to florfenicol powder bioavailability sustained release formulation, Pharmaceuticals: Formulation and Compounding and other aspects.Synthetic Route of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 31, 2009, Hu, Shuai; Ouyang, Wuqing; Yang, Xuefeng published an article.Formula: C17H24N4O6 The title of the article was Preparation and quality evaluation of compound tilmicosin nanoemulsion. And the article contained the following:

The aim of this paper was to study the preparation and quality evaluation of compound tilmicosin and trimethoprim lactate nanoemulsion (TMS-TMPL-NE). The formulations of TMS-TMPL-NE were optimized by protracting the pseudoternary phase diagrams, taking iso-Pr myristate (IPM), Tween 80, m(ethanol)/m(propylene glycol, PG) = 3, phosphoric acid, TMS and TMPL to prepare TMS-TMPL-NE. TEM and Particle Sizing System reviewed its shape and particle size distribution and constant temperature accelerated experimentation to verify its stability. TEM presented TMS-TMPL-NE as small spherical drops, evenly distributed, with mean diameter of 12.4 nm and polydispersity index of 0.051. The constant temperature acceleration experimentation showed that it was not delaminated, still clear and lucent. The optimal preparation procedure of TMS-TMPL-NE was simple, and the stability of the prepared nanoemulsion was good. It was expected to be applicable to the veterinarian clinic. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Formula: C17H24N4O6

The Article related to compound tilmicosin nanoemulsion preparation quality evaluation, Pharmaceuticals: Formulation and Compounding and other aspects.Formula: C17H24N4O6

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 8, 2014, Liu, Guilan; Liu, Tuo; Xie, Lingling published a patent.Product Details of 23256-42-0 The title of the patent was Method for preparing soluble powder of sulfanilamide salt and trimethoprim. And the patent contained the following:

The invention relates to method for preparing sulfanilamide salt and trimethoprim soluble powder. The sulfanilamide salt and trimethoprim soluble powder contains sulfanilamide salt 5∼50%, trimethoprim lactate 1∼10, coated dispersant 10∼25% and alk. excipient added to 100%. The preparation method comprises (1) weighing coated dispersant, adding trimethoprim lactate, stirring to mix well to obtain mixture A; and (2) adding sulfanilamide salt to mixture A, adding alk. excipient to 100%, stirring to obtain sulfanilamide salt and trimethoprim soluble powder. Special processing of sulfanilamide salt and trimethoprim can make sulfanilamide salt alk. drug and trimethoprim acidic drug simultaneously disperse uniformly in water, not precipitate within 2 h, and have stable content of active components. The invention is convenient for animal use, has good curative effect, safe and reliable property, good stability, no adverse reaction, compared with premix it has remarkable application advantage. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Product Details of 23256-42-0

The Article related to sulfanilamide trimethoprim soluble powder veterinary antibiotic, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On November 5, 2014, Wang, Yuwan; Pan, Zhende; Dai, Xiaoxi; Ren, Yanan; Shen, Li published a patent.Formula: C17H24N4O6 The title of the patent was A preparation method of tulathromycin oily injection. And the patent contained the following:

The invention relates to a preparation method of tulathromycin oily injection with co-solvent, which is glycerol formal/benzyl benzoate/oily medium, wherein the oily medium comprises Et oleate, and iso-Pr myristate, and the formulation also includes hydrogenated castor oil and soy lecithin. The co-solvent can also prepare a compound preparation of tulathromycin and trimethoprim lactate. The preparation has good stability, good physiol. tolerance, and high drug loading coefficient, so that it is an animal-oriented oily injection both good in slow release and controlled release. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Formula: C17H24N4O6

The Article related to tulathromycin oily injection formulation cosolvent antioxidant, Pharmaceuticals: Formulation and Compounding and other aspects.Formula: C17H24N4O6

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On January 23, 2013, Wang, Lei published a patent.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate The title of the patent was Preparation method of compound oral liquid of neomycin sulfate and its application in treating severe diarrhea of poultry. And the patent contained the following:

The title compound oral liquid comprises neomycin sulfate 8-15, berberine hydrochloride 3-6, trimethoprim lactate 1-3, astragalan for injection 10-20, levamisole hydrochloride 2-4, acetaminophen 5-15 and water for injection 60-80 weight parts. The preparation method consists of adding 2/3 water for injection (60-70°C), adding remaining materials in sequential order, stirring, adding remaining water for injection, filling with nitrogen gas, adding 0.05-0.2% active carbon, decoloring for 20-30 min, filtering off carbon, detecting content and pH value, filtering at 0.45 or 0.6 um, bottling, and sterilizing with 100°C steam for 30 min. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

The Article related to compound oral liquid neomycin sulfate severe diarrhea poultry, Pharmaceuticals: Formulation and Compounding and other aspects.Quality Control of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On August 22, 2012, Ouyang, Wuqing; Zheng, Xingxing; Ouyang, Shenyu published a patent.Computed Properties of 23256-42-0 The title of the patent was Preparation of pharmaceutical nanoemulsion composition containing erythromycin ethylsuccinate used as antibacterial agent. And the patent contained the following:

The title composition with particle size of 1-100 nm contains (by weight%) erythromycin ethylsuccinate 0.2-4, trimethoprim lactate 0.03-1, surfactant 25-38, cosurfactant 2-11, oil 2.5-9.8% and distilled water as balance. The surfactant is Tween-80, RH-40 or EL-40. The cosurfactant is anhydrous ethanol, 1,2-propylene glycol, isopropanol and/or polyethylene glycol 600. The oil is carvacrol, cinnamaldehyde, iso-Pr myristate and/or triacetin. The preparation method comprises the steps of: (1) dissolving erythromycin ethylsuccinate with oil and cosurfactant to obtain a oil phase, (2) dissolving trimethoprim lactate with distilled water to obtain a water phase, and (3) stirring the oil phase and surfactant at room temperature while dripping the water phase, and stirring to obtain clear and transparent solution The inventive nanoemulsion can be used for treating mycoplasma pneumonia, urogenital tract infection, pertussis, skin and soft tissue infection, and respiratory tract infection induced by sensitive organism. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Computed Properties of 23256-42-0

The Article related to erythromycin ethylsuccinate nanoemulsion antibacterial agent, Pharmaceuticals: Formulation and Compounding and other aspects.Computed Properties of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

On April 24, 2013, Zhou, Qingfu; Liu, Wenli published a patent.Synthetic Route of 23256-42-0 The title of the patent was Compound for erythromycin thiocyanate composition for preventing and curing bacterial and mycoplasma infection in fowls and preparation method thereof. And the patent contained the following:

The invention relates to a compound for erythromycin thiocyanate composition for preventing and curing bacterial and mycoplasma infection in fowls and preparation method thereof. The composition comprises (by weight part): erythromycin thiocyanate 10-15, neomycin sulfate 10-20, trimethoprim lactate 4-7, and anhydrous glucose 58-76. The beneficial effects of the invention include reasonable prescription, simple preparation, obvious curative effect. Clin. application proves that the composition has specific effect on treating bacterial and mycoplasma infection of poultry. The experimental process involved the reaction of 5-(3,4,5-Trimethoxybenzyl)pyrimidine-2,4-diamine 2-hydroxypropanoate(cas: 23256-42-0).Synthetic Route of 23256-42-0

The Article related to erythromycin thiocyanate bacteria mycoplasma infection fowl, Pharmaceuticals: Formulation and Compounding and other aspects.Synthetic Route of 23256-42-0

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia